The lupus patient with positive rheumatoid factor

Fedrigo, Aiessa Zanchett; Santos, Thiago Alberto Fernandes Gomes Dos; Nisihara, Renato; Skare, Thelma

doi:10.1177/0961203318759607

Cited by 15 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, RF is not a specific antibody unique to RA. In lupus [14], Sjogren's syndrome [15], systemic sclerosis [16], and hepatitis C virus getrelated arthropathy (HCVrA) [17], these disease positive rates are not low as expected. A systematic review showed that the sensitivity of RF for early diagnosis was from 77 to 80%, and the specificity was between 33 and 77% in 1987 diagnostic ACR criteria [18].…”

Section: Electronic Supplementary Materialsmentioning

confidence: 84%

Diagnostic accuracy of anti-keratin antibody for rheumatoid arthritis: a meta-analysis

Wang

Cheng

et al. 2019

Clin Rheumatol

View full text Add to dashboard Cite

Objectives Anti-keratin antibody (AKA) is a serum antibody for patients with rheumatoid arthritis (RA), and it has a high specificity. Diagnostic role of AKA in RA was evaluated in this study. Methods PubMed, EMBASE, and Web of Science were searched to acquire eligible studies. Articles published before 15 March 2018 were considered to be included. Quality Assessment of Diagnostic Accuracy Studies 2 was used to evaluate the risk of bias and application concern of the included articles. Pooled analysis of diagnostic indicators of AKA for RA was conducted by using a random effects model. Subgroup analysis was employed to explore the potential influencing factors. RevMan 5.3, Stata 11.0, and Meta-DiSc 1.4 software were used in this study. Results A total of 15 studies (2350 positive and 2067 negative participants) were included. The pooled sensitivity was 0.46 (95% CI 0.44-0.48), pooled specificity was 0.94 (95% CI 0.93-0.95), and pooled diagnostic odds ratio was 15.86 (95% CI 9.48-26.52). In addition, the area under the curve was 0.7194. Conclusions The current evidence indicated that AKA has high diagnostic specificity in RA and may be useful for RA diagnostic application in clinic.

show abstract

Section: Electronic Supplementary Materialsmentioning

confidence: 84%

Diagnostic accuracy of anti-keratin antibody for rheumatoid arthritis: a meta-analysis

Wang

Cheng

et al. 2019

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…A variable proportion between 20–30% patients with adult-onset SLE are positive for rheumatoid factor and this correlated with clinical features of arthritis [ 185 , 186 ]. In contrast, a smaller proportion of adults with SLE have been found positive for anti-citrullinated cyclic peptides (CCP) antibodies, but this biomarker was associated with erosive arthritis in adults with SLE [ 187 ], in particular in SLE patients with higher titres [ 188 ].…”

Section: Arthritis Biomarkersmentioning

confidence: 99%

Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus

Greenan-Barrett

Doolan

Shah

et al. 2021

IJMS

View full text Add to dashboard Cite

Juvenile systemic lupus erythematosus (JSLE) is characterised by onset before 18 years of age and more severe disease phenotype, increased morbidity and mortality compared to adult-onset SLE. Management strategies in JSLE rely heavily on evidence derived from adult-onset SLE studies; therefore, identifying biomarkers associated with the disease pathogenesis and reflecting particularities of JSLE clinical phenotype holds promise for better patient management and improved outcomes. This narrative review summarises the evidence related to various traditional and novel biomarkers that have shown a promising role in identifying and predicting specific organ involvement in JSLE and appraises the evidence regarding their clinical utility, focusing in particular on renal biomarkers, while also emphasising the research into cardiovascular, haematological, neurological, skin and joint disease-related JSLE biomarkers, as well as genetic biomarkers with potential clinical applications.

show abstract

“…Clinical manifestation of SLE is heterogeneous and can affect multiple organs. Approximately 25% of SLE patients have RF ( 13 ), but these patients can also have anti-nuclear antibodies (ANA) and anti- double-stranded (ds) DNA antibodies.…”

Section: Introductionmentioning

confidence: 99%

False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases

et al. 2021

View full text Add to dashboard Cite

Patients with chronic inflammatory diseases are often treated with immunosuppressants and therefore are of particular concern during the SARS-CoV-2 pandemic. Serological tests will improve our understanding of the infection and immunity in this population, unless they tests give false positive results. The aim of this study was to evaluate the specificity of SARS-Cov-2 serological assays using samples from patients with chronic inflammatory diseases collected prior to April 2019, thus defined as negative. Samples from patients with multiple sclerosis (MS, n=10), rheumatoid arthritis (RA, n=47) with or without rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibodies (anti-CCP2) and systemic lupus erythematosus (SLE, n=10) with or without RF, were analyzed for SARS-CoV-2 antibodies using 17 commercially available lateral flow assays (LFA), two ELISA kits and one in-house developed IgG multiplex bead-based assay. Six LFA and the in-house validated IgG assay correctly produced negative results for all samples. However, the majority of assays (n=13), gave false positive signal for samples from patients with RA and SLE. This was most notable in samples from RF positive RA patients. No false positive samples were detected in any assay using samples from patients with MS. Poor specificity of commercial serological assays could possibly be, at least partly, due to interfering antibodies in samples from patients with chronic inflammatory diseases. For these patients, the risk of false positivity should be considered when interpreting results of the SARS-CoV-2 serological assays.

show abstract

The lupus patient with positive rheumatoid factor

Cited by 15 publications

References 29 publications

Diagnostic accuracy of anti-keratin antibody for rheumatoid arthritis: a meta-analysis

Diagnostic accuracy of anti-keratin antibody for rheumatoid arthritis: a meta-analysis

Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus

False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases

Contact Info

Product

Resources

About